Stay updated on Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedRemoved the government funding lapse notice about potential delays; the page’s essential study information (eligibility criteria, locations, and treatment arms) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe updates are minor UI/layout adjustments and small textual edits on the Study Details page. Core information such as the study title, NCT number, condition, intervention, and listed locations remains unchanged.SummaryDifference0.3%

- Check71 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference4%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedPage now shows revision v3.0.2, replacing v3.0.1, indicating a new release; aside from removing the 'Back to Top' element, no substantive content changes are detected.SummaryDifference0.2%

Stay in the know with updates to Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.